This year, the International Compression Club founded by Hugo Partsch, PhD will be meeting as part of the XVII World Meeting of the International Union of Phlebology (IUP) in Boston, MA on September 8.
Ed Arkans, MEng, President of ACI Medical, LLC, is to speak alongside other experts in compression medicine and technology and serve as a chairman during the morning session.
From the ICC website:
Compression therapy is an extremely effective treatment modality, the efficacy of which is frequently underestimated or neglected. There are important areas in medicine in which compression therapy (CT) could be beneficial to patients but is not used because of lack of knowledge of the prescribers. There are countries in which CT has no tradition and is unknown to patients who could profit from it. Only few medical indications for CT are endorsed by evidence based medicine.At the present time it is extremely difficult to convince the vast group of medical people who are not specifically interested or lack knowledge about the merits of good compression, because the arguments in favour of CT are weak, and our standards are vague or non-existent. In addition, patients are often unaware of CT or do not experience the benefits due to poor compliance.As long as we are unable to give the right dosage for the individual patient and as long as we do not agree how this should be measured, then CT will remain an obscure treatment modality, underestimated and underreported.
Arkans will present on the topic “Arterial Device Optimization,” which highlights the importance of treating circulatory diseases such as PAD with an optimized arterial device when surgery is contraindicated.
Peripheral arterial disease (PAD) is a chronic disease of the lower and upper extremities in which plaque blocks the arteries or the artery walls harden (atherosclerosis), causing a decrease in blood flow. PAD-related conditions include intermittent claudication, non-healing wounds and critical limb ischemia. In severe cases, endovascular or an open bypass procedures are indicated. However, many patients are contraindicated for surgical intervention.
Arkans is the primary engineer behind ArtAssist®…The Arterial Assist Device®, which was developed by vascular surgeons. With a deep understanding of the underlying physiology of increasing arterial blood flow, the team focused on results that would clinically benefit patients with poor peripheral circulation. Independent published clinical studies show 86% to 94% limb salvage rates for inoperable patients who used the ArtAssist® device.